HIGHLIGHTS
- who: Klaus-Peter Dieckmann from the Portuguese Institute, University of California, San Diego, United States have published the research: Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma, in the Journal: (JOURNAL) of July/15,/2019
- what: This study provides the first piece of evidence for the understanding that normal M371 levels at the end of chemotherapy for metastatic seminoma do likely indicate the absence of viable residual seminoma.
SUMMARY
Cisplatin-based chemotherapy can provide a cure . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.